论文部分内容阅读
高胆固醇血症是冠状动脉粥样硬化的主要易患因子。血浆大部分胆固醇是以低密度脂蛋白(LDL-C)的形式存在,其中高密度脂蛋白(HDL-C)与冠状动脉硬化呈负性相关,甘油三酯则主要存在于乳糜微粒(CM)和极低密度脂蛋白(VLDL)中,血浆胆固醇中内源性者约占2/3,因而干扰胆固醇生物合成是一种合理的治疗方法。Lovastatin(Merck)
Hypercholesterolemia is a major predisposing factor for coronary atherosclerosis. Most plasma cholesterol is in the form of low density lipoprotein (LDL-C), of which high density lipoprotein (HDL-C) is negatively correlated with coronary arteriosclerosis and triglycerides are mainly present in chylomicrons (CM) And very low density lipoprotein (VLDL), plasma endogenous cholesterol accounts for about 2/3, thus interfering with cholesterol biosynthesis is a reasonable treatment. Lovastatin (Merck)